Who
William Fairey
Director
Company insider
Files Form 4 as: Director, Mirum Pharmaceuticals; Director, KalVista Pharmaceuticals; Director, Rein Therapeutics; EVP, Chief Commercial Officer, MyoKardia; Chief Operating Officer, ChemoCentryx.
In numbers
- Trades disclosed
- 38
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $352K
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 3 Jan 2018
- Last trade
- 15 Jun 2026
- Last filed
- 17 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jun 2026filed 17 Jun 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,772 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,980 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,772 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,980 at $0.00 | filing |
| 11 Jun 2026filed 11 Jun 2026 | KalVista Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —17,000 | filing |
| 11 Jun 2026filed 11 Jun 2026 | KalVista Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,000 | filing |
| 11 Jun 2026filed 11 Jun 2026 | KalVista Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —30,000 | filing |
| 11 Jun 2026filed 11 Jun 2026 | KalVista Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —17,000 | filing |
| 11 Jun 2026filed 11 Jun 2026 | KalVista Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —10,000 | filing |
| 11 Jun 2026filed 11 Jun 2026 | KalVista Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —30,000 | filing |
| 1 Oct 2025filed 2 Oct 2025 | KalVista Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 23 Jul 2025filed 23 Jul 2025 | RNTX Rein Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,500 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $155K3,203 at $48.42 | filing |
| 29 May 2025filed 2 Jun 2025 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,703 at $0.00 | filing |
| 29 May 2025filed 2 Jun 2025 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,268 at $0.00 | filing |
| 29 May 2025filed 2 Jun 2025 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,977 at $0.00 | filing |
| 29 May 2025filed 2 Jun 2025 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —5,703 | filing |
| 2 Dec 2024filed 6 Dec 2024 | RNTX Rein Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 3 Oct 2024filed 4 Oct 2024 | KalVista Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 20 Aug 2024filed 22 Aug 2024 | RNTX Rein Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,725 at $0.00 | filing |
News
Mirum Pharmaceuticals to report Livmarli trial results Monday (MIRM:NASDAQ)MIRM · seekingalpha.com · 12 Oct 2026
0 headlines in the last 90 days name William Fairey; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.